在流感相关急性呼吸窘迫综合征中成功脱离为期65天的体外膜肺氧合治疗。
Successful weaning from 65-day extracorporeal membrane oxygenation therapy in influenza-associated acute respiratory distress syndrome.
作者信息
Buchtele Nina, Schellongowski Peter, Bojic Andja, Hermann Alexander, Robak Oliver, Lamm Wolfgang, Staudinger Thomas
机构信息
Department of Internal Medicine I - Intensive Care Unit 13i2, Medical University of Vienna, Vienna - Austria.
出版信息
Int J Artif Organs. 2016 Jul 4;39(5):249-52. doi: 10.5301/ijao.5000501. Epub 2016 Jun 23.
INTRODUCTION
Data on prolonged extracorporeal membrane oxygenation (ECMO) usage in influenza associated acute respiratory distress syndrome (ARDS) are lacking. Furthermore, no consensus exists on when to terminate ECMO treatment in refractory cases. This report highlights additional treatment measures and complications in prolonged ECMO therapy and discusses associated ethical burdens.
CASE REPORT
We report on a 64-year-old man with confirmed H1N1 influenza virus infection who was successfully weaned from 65-day ECMO treatment with an excellent outcome.
CONCLUSIONS
Our experience suggests that prolonged ECMO therapy may be provided as long as only 1-organ failure exists and no lung fibrosis occurs. Active physical therapy, facilitated by ECMO treatment, is crucial and should be performed as early as possible.
引言
关于在流感相关急性呼吸窘迫综合征（ARDS）中长时间使用体外膜肺氧合（ECMO）的数据尚缺。此外，对于难治性病例何时终止ECMO治疗尚无共识。本报告强调了长时间ECMO治疗中的额外治疗措施及并发症，并讨论了相关的伦理负担。
病例报告
我们报告了一名确诊感染H1N1流感病毒的64岁男性，其成功脱离了为期65天的ECMO治疗，结局良好。
结论
我们的经验表明，只要仅存在单一器官功能衰竭且未发生肺纤维化，就可进行长时间的ECMO治疗。由ECMO治疗辅助的积极物理治疗至关重要，且应尽早进行。
Zotero 插件